Yahoo
    NasdaqCM - Nasdaq Real Time Price USD

    Avalo Therapeutics, Inc. (AVTX)

    6.93 +0.30 (+4.52%)
    At close: November 6 at 4:00:01 PM EST
    7.05 +0.12 (+1.73%)
    After hours: November 6 at 5:26:20 PM EST
    Trade AVTX on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for AVTX
    • Previous Close 6.63
    • Open 6.90
    • Bid 4.98 x 200
    • Ask 8.51 x 200
    • Day's Range 6.53 - 7.01
    • 52 Week Range 6.53 - 24.27
    • Volume 1,107,294
    • Avg. Volume 1,577,935
    • Market Cap (intraday) 371.656M
    • Beta (5Y Monthly) 0.75
    • PE Ratio (TTM) --
    • EPS (TTM) -2.26
    • Earnings Date Nov 5, 2026
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 36.60
    • Zacks Rating Neutral

    Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

    www.avalotx.com

    33

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about Avalo Therapeutics, Inc.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    AVTX
    61.84%
    S&P 500 (^GSPC)
    7.76%

    1-Year Return

    AVTX
    55.06%
    S&P 500 (^GSPC)
    9.77%

    3-Year Return

    AVTX
    71.41%
    S&P 500 (^GSPC)
    68.96%

    5-Year Return

    AVTX
    99.90%
    S&P 500 (^GSPC)
    57.04%

    Earnings Trends

    View More

    Earnings Per Share

    GAAP
    Normalized
    GAAP
    Normalized

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q3 FY26
    Revenue --
    Earnings -18.95M
    Profit Margin 0.00%

    Q4

    FY25

    Q1

    FY26

    Q2

    FY26

    Q3

    FY26

    -30M
    -20M
    -10M
    0
    -20000.0%
    -15000.0%
    -10000.0%
    -5000.0%
    0.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    10.00
    36.60 Average
    6.93 Current
    60.00 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 11/6/2026
    Analyst Wedbush
    Rating Action Maintains
    Rating Outperform
    Price Action Lowers
    Price Target 22 -> 20
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      0.00%

    • Return on Assets (ttm)

      -18.50%

    • Return on Equity (ttm)

      -36.27%

    • Revenue (ttm)

      59k

    • Net Income Avi to Common (ttm)

      -100.33M

    • Diluted EPS (ttm)

      -2.26

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      400.28M

    • Total Debt/Equity (mrq)

      0.05%

    • Levered Free Cash Flow (ttm)

      -23.27M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    TPST Tempest Therapeutics, Inc.
    0.3806 -1.39%
    ZVSA ZyVersa Therapeutics, Inc.
    0.0010 0.00%
    ICU SeaStar Medical Holding Corporation
    1.8800 -2.08%
    NVOS Novo Integrated Sciences, Inc.
    0.0006 0.00%
    RNAZ TransCode Therapeutics, Inc.
    1.4900 -1.32%
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: